Lido Advisors LLC Buys 4,718 Shares of IQVIA Holdings Inc. $IQV

Lido Advisors LLC grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 106.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,145 shares of the medical research company’s stock after purchasing an additional 4,718 shares during the period. Lido Advisors LLC’s holdings in IQVIA were worth $2,459,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Compass Financial Management LLC increased its position in IQVIA by 31.9% in the 3rd quarter. Compass Financial Management LLC now owns 157 shares of the medical research company’s stock valued at $42,000 after buying an additional 38 shares in the last quarter. North Dakota State Investment Board boosted its holdings in IQVIA by 0.8% in the third quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company’s stock worth $1,361,000 after acquiring an additional 40 shares in the last quarter. Boston Trust Walden Corp boosted its holdings in IQVIA by 1.9% in the third quarter. Boston Trust Walden Corp now owns 2,650 shares of the medical research company’s stock worth $712,000 after acquiring an additional 50 shares in the last quarter. Apella Capital LLC grew its stake in IQVIA by 4.7% in the third quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock valued at $319,000 after acquiring an additional 55 shares during the period. Finally, Brighton Jones LLC increased its holdings in shares of IQVIA by 0.7% during the third quarter. Brighton Jones LLC now owns 8,151 shares of the medical research company’s stock valued at $2,191,000 after acquiring an additional 58 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,446 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the transaction, the insider directly owned 24,989 shares in the company, valued at approximately $6,967,682.87. This trade represents a 15.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the transaction, the insider owned 10,890 shares in the company, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on IQV shares. Stifel Nicolaus upped their target price on IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. Jefferies Financial Group lifted their price target on shares of IQVIA from $220.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Mizuho boosted their price target on shares of IQVIA from $275.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. Royal Bank Of Canada upped their price objective on shares of IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a report on Tuesday, September 29th. Finally, UBS Group began coverage on shares of IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $294.21.

IQVIA Stock Down 2.1%

IQV traded down $5.67 during midday trading on Friday, reaching $265.44. 1,986,072 shares of the company were exchanged, compared to its average volume of 1,407,100. The company has a market cap of $43.74 billion, a price-to-earnings ratio of 32.25, a price-to-earnings-growth ratio of 2.41 and a beta of 1.16. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $284.50. The company’s fifty day moving average price is $267.55 and its 200 day moving average price is $211.88. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. The company had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The company’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same quarter last year, the company earned $3.00 earnings per share. As a group, analysts expect that IQVIA Holdings Inc. will post 11.53 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.